After Hours
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours.
Stocks Info
This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. The current market capitalization of Acumen Pharmaceuticals Inc is $101.76M. A total of 0.68 million shares were traded on the day, compared to an average of 430.33K shares.
In the most recent transaction, Zuga Matt sold 28,902 shares of ABOS for 1.72 per share on Jan 23 ’25. After the transaction, the CFO & Chief Business Officer now owns 231,744 company shares. In a previous transaction on Jan 21 ’25, Zuga Matt sold 4,364 shares at 1.60 per share. ABOS shares that CFO & Chief Business Officer owns now total 260,646.
Among the insiders who sold shares, OConnell Daniel Joseph disposed of 12,619 shares on Jan 21 ’25 at a per-share price of $1.59. This resulted in the Chief Executive Officer holding 667,488 shares of ABOS after the transaction. In another insider transaction, Meisner Derek M sold 3,418 shares at $1.59 per share on Jan 21 ’25. Company shares held by the Chief Legal Officer & Corp Sec now total 161,127.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. In terms of 52-week highs and lows, ABOS has a high of $3.60 and a low of $0.86.
As of this writing, ABOS has an earnings estimate of $-0.46 per share for the current quarter. EPS was calculated based on a consensus of 2.0 estimates, with a high estimate of $-0.41 per share and a lower estimate of $-0.5.
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. ABOS’s latest balance sheet shows that the firm has $194.24M in Cash & Short Term Investments as of fiscal 2021. There were $0.00 in debt and $5.15M in liabilities at the time. Its Book Value Per Share was $2.57, while its Total Shareholder’s Equity was $225.18M.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ABOS is Buy with a score of 5.00.
